Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
NCT Number:
NCT02201992
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lung
Study Objectives:
To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) over placebo for patients with stage IB ? 4cm, II and IIIA, ALK-positive NSCLC following surgical resection.
Study Documents
(MUSC NetID required for document access)